Methotrexate should not be used for patients with end-stage kidney disease
- PMID: 17091912
- DOI: 10.1179/acb.2006.028
Methotrexate should not be used for patients with end-stage kidney disease
Abstract
Methotrexate is a widely used disease-modifying anti-rheumatic drug. Its effectiveness has been proven in placebo-controlled trials and in comparison with other disease-modifying anti-rheumatic drugs. The pharmacokinetics of methotrexate are highly variable and unpredictable. In patients with normal renal function, the recommended dose in rheumatoid arthritis ranges between 7.5 and 15 mg/week, but in recent years, even dosages up to 25 mg weekly are used. Toxicity includes myelosuppression, gastrointestinal adverse effects, hepatotoxicity and pneumonitis. Renal impairment and age are considered major risk factors for developing methotrexate toxicity, but studies show conflicting results. Whether methotrexate can be administered to patients with end-stage kidney disease has not been formally tested. The present case illustrates the severe side effects of low-dose methotrexate treatment in a patient with end-stage kidney disease. Seven other cases have reported similar and even more severe and irreversible consequences after low-dose regimen. In view of these side effects we strongly recommend to monitor toxicity rigorously in patients with stage 3 or stage 4 kidney disease and not to use methotrexate in patients with stage 5 kidney disease.
Similar articles
-
Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate.J Clin Rheumatol. 2009 Jun;15(4):177-80. doi: 10.1097/RHU.0b013e3181a61f2d. J Clin Rheumatol. 2009. PMID: 19502905 Review.
-
Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.Curr Opin Rheumatol. 2008 May;20(3):251-6. doi: 10.1097/BOR.0b013e3282fb7caa. Curr Opin Rheumatol. 2008. PMID: 18388514 Review.
-
Gynecomastia and sexual impotence associated with methotrexate treatment.J Rheumatol. 2002 Aug;29(8):1793-4. J Rheumatol. 2002. PMID: 12180746
-
Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate.Clin Exp Rheumatol. 2001 Nov-Dec;19(6):727-30. Clin Exp Rheumatol. 2001. PMID: 11791648
-
Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis?J Rheumatol. 1995 Nov;22(11):2191. J Rheumatol. 1995. PMID: 8596175 No abstract available.
Cited by
-
From Treatment to Tragedy: Severe Methotrexate Toxicity With Mucocutaneous Ulcers, Myelosuppression, and Nephropathy.Cureus. 2024 Apr 8;16(4):e57797. doi: 10.7759/cureus.57797. eCollection 2024 Apr. Cureus. 2024. PMID: 38721177 Free PMC article.
-
Drug-drug interaction assessment based on a large-scale spontaneous reporting system for hepato- and renal-toxicity, and thrombocytopenia with concomitant low-dose methotrexate and analgesics use.BMC Pharmacol Toxicol. 2024 Feb 1;25(1):13. doi: 10.1186/s40360-024-00738-6. BMC Pharmacol Toxicol. 2024. PMID: 38303016 Free PMC article.
-
Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates.Int J Rheum Dis. 2022 Oct;25(10):1107-1122. doi: 10.1111/1756-185X.14406. Epub 2022 Aug 2. Int J Rheum Dis. 2022. PMID: 35916205 Free PMC article. Review.
-
Comparing four different methods for the management of ectopic pregnancy: A cross-sectional study.Int J Reprod Biomed. 2022 Apr 21;20(3):177-184. doi: 10.18502/ijrm.v20i3.10709. eCollection 2021 Mar. Int J Reprod Biomed. 2022. PMID: 35571502 Free PMC article.
-
Anti-TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe?Eur J Rheumatol. 2022 Apr;9(2):68-74. doi: 10.5152/eurjrheum.2022.21099. Eur J Rheumatol. 2022. PMID: 35546331 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
